Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00606086 |
|
Recruitment Status :
Completed
First Posted : February 1, 2008
Results First Posted : June 3, 2014
Last Update Posted : June 27, 2014
|
Sponsor:
GlobeImmune
Information provided by (Responsible Party):
GlobeImmune
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections including EVR, ETR, and SVR.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Genotype 1 Chronic Hepatitis C | Drug: GI-5005 Drug: Pegylated Interferon and Ribavirin | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 140 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone, and GI-5005 Salvage of Standard of Care Failures, in Patients With Genotype 1 Chronic Hepatitis C Infection |
| Study Start Date : | December 2007 |
| Actual Primary Completion Date : | November 2012 |
| Actual Study Completion Date : | November 2012 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 1
GI-5005 monotherapy continuing on to triple therapy
|
Drug: GI-5005
40YU, subcutaneous
Other Name: Pegasys and Ribavirin |
|
Active Comparator: 2
Standard of care alone
|
Drug: GI-5005
40YU, subcutaneous
Other Name: Pegasys and Ribavirin Drug: Pegylated Interferon and Ribavirin Pegylated interefron is an injection and ribavirin is an oral tablet
Other Name: Pegasys and Ribavirin |
Primary Outcome Measures :
- EVR (Early Virologic Response) [ Time Frame: At 12 weeks of treatment ]Early Virologic Response (EVR) is a response measured by the reduction of virus in the blood after 12 weeks of treatment.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Chronic hepatitis C infection with genotype 1 based on serum positivity for HCV RNA or a positive test for serum anti-HCV antibody for at least 6 months;
- One of the following response criteria based on response to prior combination therapy with pegylated or non-pegylated interferon plus ribavirin:
Non-Responders
- Poor responders - a subset of non-responders who achieved > 1 log10 but < 2 log10 reduction in HCV RNA after a minimum of 12 weeks of prior interferon based therapy.
- Partial responders - a subset of non-responders who achieve at least a 2 log10 reduction in HCV RNA by 12 weeks, but do not achieve an end of treatment response (ETR defined as HCV RNA negativity by PCR assay at the end of a minimum of 6 months of therapy).
Naive
- Patients who are treatment naïve and have refused IFN therapy for reasons other than contraindication.
- Signed, written, informed consent from the patient or legal representative before any study-specific procedures are performed;
- Liver biopsy within 3 years of the screening visit, documenting extent of liver disease consistent with chronic hepatitis C with evidence of inflammation and/or fibrosis. Liver biopsy within 1 year for subjects consenting to paired biopsy testing. Eight unstained liver biopsy slides are required for the baseline sample and post-treatment sample for use in central blinded evaluation for paired biopsy testing;
- Age ≥ 18 years;
- Negative scratch test (immediate hypersensitivity, IgE mediated) to S. cerevisiae.
Exclusion Criteria:
- History of decompensated liver disease, including but not restricted to, portal hypertension as manifested by a known history of gastroesophageal varices, variceal bleeding, ascites or encephalopathy, histopathologic or clinical evidence of cirrhosis, hepatocellular carcinoma, or renal impairment consistent with hepatorenal syndrome;
- History of significant non-HCV chronic liver disease, i.e. alcoholic hepatitis, autoimmune hepatitis;
- Null response to prior IFN plus ribavirin therapy, defined as patients that have received at least 12 weeks of interferon-based treatment with < 1 log10 reduction in viral load;
- Subjects treated with more than 1 complete hepatitis C regimen (subjects with a history of 1 complete prior regimen and a second incomplete prior regimen may be eligible upon discussion with and approval of the medical monitor);
- Subjects that required a dose reduction of >25% of the planned exposure of IFN or >50% of their planned ribavirin exposure during their previous interferon/ribavirin treatment;
- Subjects that required growth factors during their previous interferon/ribavirin treatment;
- Subjects that received small molecule inhibitor therapy combined with an interferon based regimen. (subjects that received small molecule inhibitor monotherapy can be included);
- Treatment for HCV infection within 28 days before screening;
- Chronic hepatitis B infection or positive hepatitis B surface antigen (HBsAg) at screening;
- Body weight >275 pounds;
- Known history of HIV infection or positive HIV antibody test at screening;
- History of Crohn's disease or ulcerative colitis;
- Concurrent therapy with herbal supplements taken specifically for the treatment of HCV (i.e. milk thistle). Wash-out of HCV related herbals for 28 days prior to Day 1. Consult sponsor before excluding potential subjects;
- Alcohol and/or IV drug abuse within the past year;
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00606086
Locations
Show 25 study locations
Sponsors and Collaborators
GlobeImmune
Additional Information:
| Responsible Party: | GlobeImmune |
| ClinicalTrials.gov Identifier: | NCT00606086 |
| Other Study ID Numbers: |
GI-5005-02 |
| First Posted: | February 1, 2008 Key Record Dates |
| Results First Posted: | June 3, 2014 |
| Last Update Posted: | June 27, 2014 |
| Last Verified: | May 2014 |
Keywords provided by GlobeImmune:
|
Hepatitis, HCV, Liver disease, HepC |
Additional relevant MeSH terms:
|
Hepatitis A Hepatitis C Hepatitis C, Chronic Hepatitis Hepatitis, Chronic Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections |
Flaviviridae Infections Interferons Ribavirin Peginterferon alfa-2a Interferon-alpha Antineoplastic Agents Antiviral Agents Anti-Infective Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Immunologic Factors Physiological Effects of Drugs |